BIONTECH SE-ADR (22UA.DE) Fundamental Analysis & Valuation

FRA:22UA • US09075V1026

Current stock price

79.55 EUR
+1.9 (+2.45%)
Last:

This 22UA.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

3

1. 22UA.DE Profitability Analysis

1.1 Basic Checks

  • In the past year 22UA has reported negative net income.
  • In the past year 22UA had a positive cash flow from operations.
  • The reported net income has been mixed in the past 5 years: 22UA reported negative net income in multiple years.
  • Each year in the past 5 years 22UA had a positive operating cash flow.
22UA.DE Yearly Net Income VS EBIT VS OCF VS FCF22UA.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B

1.2 Ratios

  • The Return On Assets of 22UA (-5.17%) is better than 63.29% of its industry peers.
  • 22UA's Return On Equity of -5.91% is fine compared to the rest of the industry. 22UA outperforms 68.35% of its industry peers.
Industry RankSector Rank
ROA -5.17%
ROE -5.91%
ROIC N/A
ROA(3y)-1.36%
ROA(5y)20.29%
ROE(3y)-1.58%
ROE(5y)25.77%
ROIC(3y)N/A
ROIC(5y)N/A
22UA.DE Yearly ROA, ROE, ROIC22UA.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 100 150

1.3 Margins

  • The Gross Margin of 22UA (83.31%) is better than 74.68% of its industry peers.
  • 22UA's Gross Margin has been stable in the last couple of years.
  • 22UA does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 83.31%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y-0.78%
22UA.DE Yearly Profit, Operating, Gross Margins22UA.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 -100 -150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. 22UA.DE Health Analysis

2.1 Basic Checks

  • 22UA does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • 22UA has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, 22UA has more shares outstanding
  • 22UA has about the same debt/assets ratio as last year.
22UA.DE Yearly Shares Outstanding22UA.DE Yearly Shares OutstandingYearly Shares Outstanding 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M 250M
22UA.DE Yearly Total Debt VS Total Assets22UA.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

2.2 Solvency

  • An Altman-Z score of 6.40 indicates that 22UA is not in any danger for bankruptcy at the moment.
  • Looking at the Altman-Z score, with a value of 6.40, 22UA is in the better half of the industry, outperforming 72.15% of the companies in the same industry.
  • 22UA has a Debt/Equity ratio of 0.01. This is a healthy value indicating a solid balance between debt and equity.
  • The Debt to Equity ratio of 22UA (0.01) is better than 79.75% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Altman-Z 6.4
ROIC/WACCN/A
WACC7.4%
22UA.DE Yearly LT Debt VS Equity VS FCF22UA.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • A Current Ratio of 7.54 indicates that 22UA has no problem at all paying its short term obligations.
  • With an excellent Current ratio value of 7.54, 22UA belongs to the best of the industry, outperforming 86.08% of the companies in the same industry.
  • 22UA has a Quick Ratio of 7.49. This indicates that 22UA is financially healthy and has no problem in meeting its short term obligations.
  • 22UA has a Quick ratio of 7.49. This is amongst the best in the industry. 22UA outperforms 86.08% of its industry peers.
Industry RankSector Rank
Current Ratio 7.54
Quick Ratio 7.49
22UA.DE Yearly Current Assets VS Current Liabilites22UA.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2017 2018 2019 2020 2021 2022 2023 2024 2025 5B 10B 15B 20B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. 22UA.DE Growth Analysis

3.1 Past

  • The earnings per share for 22UA have decreased strongly by -69.06% in the last year.
  • 22UA shows a small growth in Revenue. In the last year, the Revenue has grown by 4.32%.
  • The Revenue has been growing by 42.88% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-69.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.74%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y-45.07%
Revenue growth 5Y42.88%
Sales Q2Q%-23.75%

3.2 Future

  • 22UA is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 10.65% yearly.
  • 22UA is expected to show a small growth in Revenue. In the coming years, the Revenue will grow by 6.05% yearly.
EPS Next Y3.55%
EPS Next 2Y4.54%
EPS Next 3Y7.69%
EPS Next 5Y10.65%
Revenue Next Year-18.09%
Revenue Next 2Y-7.27%
Revenue Next 3Y-2.12%
Revenue Next 5Y6.05%

3.3 Evolution

  • The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
22UA.DE Yearly Revenue VS Estimates22UA.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 5B 10B 15B
22UA.DE Yearly EPS VS Estimates22UA.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 10 20 30

More info and screens

Find the best growth stocksShow best growing peers

0

4. 22UA.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for 22UA. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for 22UA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
22UA.DE Price Earnings VS Forward Price Earnings22UA.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 -10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
22UA.DE Per share data22UA.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 20 40 60

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y4.54%
EPS Next 3Y7.69%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. 22UA.DE Dividend Analysis

5.1 Amount

  • 22UA does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

22UA.DE Fundamentals: All Metrics, Ratios and Statistics

BIONTECH SE-ADR

FRA:22UA (4/10/2026, 7:00:00 PM)

79.55

+1.9 (+2.45%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-10
Earnings (Next)05-05
Inst Owners20.5%
Inst Owner ChangeN/A
Ins Owners1.15%
Ins Owner ChangeN/A
Market Cap20.12B
Revenue(TTM)2.87B
Net Income(TTM)-1.14B
Analysts80
Price Target114.17 (43.52%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-257.36%
Min EPS beat(2)-559.15%
Max EPS beat(2)44.42%
EPS beat(4)3
Avg EPS beat(4)-118.52%
Min EPS beat(4)-559.15%
Max EPS beat(4)44.42%
EPS beat(8)5
Avg EPS beat(8)-22.37%
EPS beat(12)8
Avg EPS beat(12)159.41%
EPS beat(16)11
Avg EPS beat(16)126.26%
Revenue beat(2)2
Avg Revenue beat(2)37.32%
Min Revenue beat(2)19.58%
Max Revenue beat(2)55.06%
Revenue beat(4)4
Avg Revenue beat(4)36.85%
Min Revenue beat(4)1.02%
Max Revenue beat(4)71.75%
Revenue beat(8)6
Avg Revenue beat(8)23.99%
Revenue beat(12)6
Avg Revenue beat(12)6.75%
Revenue beat(16)9
Avg Revenue beat(16)10.93%
PT rev (1m)-3.97%
PT rev (3m)-4.29%
EPS NQ rev (1m)-15.97%
EPS NQ rev (3m)-3.43%
EPS NY rev (1m)-28.5%
EPS NY rev (3m)-37.34%
Revenue NQ rev (1m)-43.58%
Revenue NQ rev (3m)-18.53%
Revenue NY rev (1m)-14.85%
Revenue NY rev (3m)-16.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 7.01
P/FCF N/A
P/OCF 44.12
P/B 1.05
P/tB 1.17
EV/EBITDA N/A
EPS(TTM)-4.7
EYN/A
EPS(NY)-4.53
Fwd EYN/A
FCF(TTM)-1.16
FCFYN/A
OCF(TTM)1.8
OCFY2.27%
SpS11.35
BVpS76.02
TBVpS68.22
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -5.17%
ROE -5.91%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 83.31%
FCFM N/A
ROA(3y)-1.36%
ROA(5y)20.29%
ROE(3y)-1.58%
ROE(5y)25.77%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.67%
GM growth 5Y-0.78%
F-Score5
Asset Turnover0.13
Health
Industry RankSector Rank
Debt/Equity 0.01
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 195.66%
Cap/Sales 26.1%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.54
Quick Ratio 7.49
Altman-Z 6.4
F-Score5
WACC7.4%
ROIC/WACCN/A
Cap/Depr(3y)244.04%
Cap/Depr(5y)246.52%
Cap/Sales(3y)20.34%
Cap/Sales(5y)12.78%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-69.06%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-215.74%
EPS Next Y3.55%
EPS Next 2Y4.54%
EPS Next 3Y7.69%
EPS Next 5Y10.65%
Revenue 1Y (TTM)4.32%
Revenue growth 3Y-45.07%
Revenue growth 5Y42.88%
Sales Q2Q%-23.75%
Revenue Next Year-18.09%
Revenue Next 2Y-7.27%
Revenue Next 3Y-2.12%
Revenue Next 5Y6.05%
EBIT growth 1Y59.75%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year14.89%
EBIT Next 3Y5.3%
EBIT Next 5Y25.01%
FCF growth 1Y-19.79%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y119.55%
OCF growth 3Y-67.74%
OCF growth 5YN/A

BIONTECH SE-ADR / 22UA.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BIONTECH SE-ADR (22UA.DE) stock?

ChartMill assigns a fundamental rating of 4 / 10 to 22UA.DE.


What is the valuation status for 22UA stock?

ChartMill assigns a valuation rating of 1 / 10 to BIONTECH SE-ADR (22UA.DE). This can be considered as Overvalued.


What is the profitability of 22UA stock?

BIONTECH SE-ADR (22UA.DE) has a profitability rating of 3 / 10.


Can you provide the expected EPS growth for 22UA stock?

The Earnings per Share (EPS) of BIONTECH SE-ADR (22UA.DE) is expected to grow by 3.55% in the next year.


Is the dividend of BIONTECH SE-ADR sustainable?

The dividend rating of BIONTECH SE-ADR (22UA.DE) is 0 / 10 and the dividend payout ratio is 0%.